Skip to main content

It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.

Switch to US ($)
affordable custom antibody generation services

Custom antibody production services

Get Guaranteed Antibodies Tailored to Your Application in as Little as 4 weeks.

Whether for therapeutics, diagnostics, or research, ProteoGenix delivers custom antibody production services tailored to your specific application. With our exclusive performance guarantee, antibodies are validated directly in your laboratory, ensuring you only move forward with antibodies that truly work in your system.

Request a Quote Talk to an Antibody Expert

A flexible and application-driven custom antibody generation platform

5
Platforms
4 monoclonal (hybridoma, single B cell screening, hybridoma, de novo) and 1 polyclonal
11
Application-guaranteed packages
Including ELISA, Western Blot, Flow cytometry, immunoprecipitation and many others
4
Therapeutic screening protocols
Neutralization, blocking, cross-reactivity assessment, and counter-screening when required

Choose the Antibody Solution That Fits Your Budget and Timeline no matter the Application

Custom monoclonal antibody

  • Strongest guarantees of the market
  • Test it in your lab before paying full price
  • 4 discovery platforms
  • Expertise in challenging antigens

 

Our Custom Monoclonal Antibody Service

Polyclonal antibody services

  • Starting at 310€
  • 28 days Expressway™ protocol
  • Large panel of species
  • Any antigen you want

 

Our Custom Polyclonal Antibody Service

Tool

Choose the right antibody strategy before you start

Answer a few questions and find the technology that best fits your target, application and timeline.

Take the 2‑min antibody quizz

Why 600+ research teams trust ProteoGenix for their custom antibody development?

Over 20 years of expertise in custom antibody production.

  • 1.

    Industry-leading performance guarantees

    Depending on your project, we guarantee either a defined number of binders or functional performance in your target application (validated in your lab).

  • 2.

    Dual antibody validation strategy

    Antibodies are tested both in-house by ProteoGenix and directly in your laboratory, ensuring reliable real-world performance in your experimental conditions.

  • 3.

    Wide species and format flexibility

    Human, mouse, humanized mouse, rat, rabbit, dog, cat, camelids, and all major antibody formats including IgG, Fab, scFv, and VHH, optimized for diverse applications.

  • 4.

    Full intellectual property ownership

    You retain complete IP rights and full ownership over all generated antibodies generated within your project.

  • 5.

    Multi-platform discovery capability

    Our diversified technologies enable alternative and complementary strategies when standard approaches fail.

  • 6.

    End-to-end scientific partnership

    From antigen design to stable cell line development, we support the entire workflow to reduce multi-vendor friction.

AIxplore® de novo antibody generation

Get your antibody in as little as 3 days with our AI-powered de novo antibody generation platform:

  • 3-Day Delivery

    Receive your antibody sequence in as little as 3 days.

  • Multi-Parameter Optimization

    Early optimization for affinity, stability and developability.

  • Virtually Any Antigen

    Rapid generation of monoclonal antibody sequences against a broad range of targets.

  • Wet-Lab Validation

    Experimental validation to support candidate selection.

  • Animal-Free Workflow

    A fully animal-free antibody discovery process from design to validation.

Risk-mitigated antibody development

How we reduce failure risk in custom antibody production

At ProteoGenix, we operate as an extension of your laboratory. Like you, our objective is to minimize development risk and maximize the probability of success from the earliest stages of the project.

To achieve this, we integrate multiple risk-mitigation strategies directly into our custom antibody development workflows.
 

Our risk-reduction framework

  • Industry-leading performance guarantees

    Depending on your application, we guarantee either a defined number of binders or functional performance in your final assay.

    This gives your project a clear success framework from the beginning.

  • Application-focused screening from the start

    Antibodies are screened directly in the assays relevant to your project, so selection is aligned with your real experimental needs.

    ELISA Flow cytometry Western blot IHC Neutralization Blocking Functional assays

  • Dual validation strategy

    Candidate antibodies are validated internally by ProteoGenix scientists and can also be tested directly in your own laboratory environment.

    This confirms real-world performance under your experimental conditions.

  • Go / No-Go project milestones

    Our workflows include predefined decision points that allow you to stop, continue, or redirect the project at critical stages.

    This helps you maintain control over timelines, budget and scientific direction.

If the initial strategy does not succeed
We do not stop at a failed first attempt.

If a project does not initially succeed, ProteoGenix can help you protect the value of the program through guarantees and alternative discovery strategies.

  • Activate your project guarantee

    You can activate your project guarantee according to the agreed project framework.

  • Switch to an alternative discovery strategy

    We can implement an alternative strategy using one of our four monoclonal antibody discovery platforms to maximize the chances of obtaining successful candidates.

    AI design Phage display Hybridoma Single B cell

Our custom antibody platforms

 

  Hybridoma Phage display Single B cell screening De novo antibody generation

NEW!

Polyclonal antibodies
Species Mouse/Rat
  • Human
  • Camelid
  • Mouse
  • Rabbit
  • Dog
  • Cat
  • Swine
  • Mouse
  • Humanized mouse
  • Rabbit
  • Human
  • Camelid
  • Mouse
  • Rabbit
  • Dog
  • Cat
  • Mouse
  • Rat
  • Rabbit
  • Llama
  • Alpaca
  • Chicken
  • Goat
  • Sheep
Formats IgG/Fab/scFv IgG/Fab/scFv/VHH IgG/Fab/scFv IgG/Fab/scFv/VHH IgG/VHH
Guarantees Applications guaranteed :
  • ELISA
  • ELISA sandwich
  • Competitive ELISA
  • Western Blot
  • Flow Cytometry
  • Immunofluorescence
  • Immunoprecipitation
  • Immunohistochemistry
  • Immunohistofluorescence
  • Modification specific
3 binders guaranteed (can vary depending on the protocol) 3 unique clones or application guarantee Project-dependent ELISA titer 1:64000
Applications Ideal for diagnostic and research (coupled to application validated protocols) Ideal for therapeutic (can be coupled to specific protocols such as neutralizing, counter-screening or cross-reacting and human or VHH libraries) and veterinary applications (coupled to cat, dog and swine libraries) Ideal for therapeutic (coupled to humanized mice) and diagnostic applications (coupled to rabbit immunization and application guaranteed protocols) Very interesting for therapeutic antibody development as developability is taken into account since the very beginning of the project (can be coupled to specific protocols such as neutralizing, counter-screening or cross-reacting and human or VHH libraries) Mainly for diagnostic and research applications
Package content
  • Antigen design and synthesis
  • Immunization
  • Fusion & screening
  • Hybridoma sub-cloning
  • Antigen check
  • Library screening & biopanning
  • Screening and validation by ELISA
  • Phage DNA extraction & antibody sequencing of positive binders
  • Antigen design and synthesis
  • Mouse immunizations
  • Single B cell sorting and screening
  • Recombinant antibody production and screening
  • AI-driven antibody generation
  • Recombinant antibody production
  • Screening and Validation by ELISA + custom protocol (optional)
  • Immunization & boost
  • ELISA titration
Deliverables
  • Up to 20 best clones (supernatant samples) at polyclonal stage for selection
  • 1 hybridoma cell line
  • 5mL culture supernatant
  • Report
  • Ownership and IP of the antibodies
  • Amino acid sequence of the best binders
  • Purified antibody (optional)
  • Intellectual property of all sequence purchased
  • Final report
  • Supernatants samples at different steps of the project for customer’s tests
  • Report
  • Amino acid sequences of the variable regions of the 3 best positive clones
  • Amino acid sequence of the best binders
  • 1mg of purified antibody
  • Intellectual property of all sequence purchased
  • Final report
10µl of pre-immune serum
300-500µl of antiserum or 10-100 µg of purified antibodies (if purification option included)
Lead time From 7 weeks From 3 weeks From 8 weeks From 3 days From 9 weeks
Price Project-dependent pricing
 
Get a quote
Project-dependent pricing
 
Get a quote
Project-dependent pricing
 
Get a quote
Project-dependent pricing
 
Get a quote
From 310€
IP Free your therapeutic innovation stays your property

A leading antibody development company

Expert Custom Antibody Production Services for Biotech and Pharmaceutical Research

ProteoGenix is a specialized provider of custom antibody production services supporting biotechnology companies, pharmaceutical developers, and academic research laboratories worldwide. Our integrated platform combines antibody discovery, sequencing, engineering, and recombinant production to accelerate antibody development from concept to validated candidate.

  • Over 6,000 antibodies successfully developed
  • 4 Weeks project turnaround
  • More than 25 years of antibody engineering expertise
  • Dedicated PhD scientific project manager

Your end-to-end custom antibody service guaranteed for your application

All Your Custom Antibody Development Steps Handled by a Single Partner in Less Than 4 Weeks

A dedicated PhD expert oversees your entire custom antibody development project, ensuring continuity and precision at every stage. From antigen design to custom cell line development, our services operate in full synergy, enabling us to manage all aspects of your project seamlessly. With more than 6000 antibodies developed, our expertise allows us to deliver solutions suited to any application. To keep you in full control, we have integrated multiple Go/No-Go checkpoints throughout the process, allowing informed decisions at every step.

Stay in Control of Your Antibody Development with Clear GO/NO-GO Decision Points
GO/NO GO

Antibody Sequencing

  • No sequence, no fee
GO/NO GO

Antibody Optimization Services

GO/NO GO

Antibody Engineering Services

GO/NO GO

Recombinant antibody production services

GO/NO GO

Why Choose Our Custom Antibody Services

Fast-Track Your Project

Thanks to our accelerated workflows, get your custom antibodies in less than 4 weeks.  This rapid turnaround helps you reduce development delays and reach your next milestone without interruption.

Guaranteed Performances

Outsourcing your antibody development can seem risky, that is why ProteoGenix offers the strongest guarantees of the market. De-risk your project for a seamless project.

Full Ownership

With ProteoGenix, you retain complete ownership and exclusive rights to all antibodies developed. No shared IP, no restrictions, and full freedom to use your results as you wish.

A complete Custom Antibody Service built for Your Success

Fast-Track Your Project

Thanks to our accelerated workflows, get your custom antibodies in less than 4 weeks.  This rapid turnaround helps you reduce development delays and reach your next milestone without interruption.

Guaranteed Performances

Outsourcing your antibody development can seem risky, that is why ProteoGenix offers the strongest guarantees of the market. De-risk your project for a seamless project.

Full Ownership

With ProteoGenix, you retain complete ownership and exclusive rights to all antibodies developed. No shared IP, no restrictions, and full freedom to use your results as you wish.

Publications featuring our custom antibody production

Publications

N Tirado et al., CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia. J Hematol Oncol 18, 69 (2025).
https://doi.org/10.1186/s13045-025-01715-0

Publications

R López-Aladid et al., Epitope mapping of SARS-CoV-2 Spike protein using naturally-acquired immune responses to develop monoclonal antibodies. Sci Rep 15, 16269 (2025).
https://doi.org/10.1038/s41598-025-00555-9

Publications

M Pitaro et al., Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms. Front Immunol 15, 1520103 (2024).
https://doi.org/10.3389/fimmu.2024.1520103

Publications

H Sihto et al., Phosphodiesterase 3 A expression in gastrointestinal stromal tumors. Virchows Arch 487, 983–991 (2025).
https://doi.org/10.1007/s00428-025-04150-1

Testimonials

Trusted by Research, Biotech, and Academic Teams Worldwide

University Bangor Dr. David Pryce

Bangor University, UK
Dr. David Pryce, Lecturer in Biomedical Sciences (Immunology)

“I requested ProteoGenix’s services for the generation of an anti-peptide monoclonal antibody to be used in my research. I required the antibody primarily for western blotting and immunoprecipitation experiments. Although the peptide antigen proved challenging in terms of immunogenicity, ProteoGenix was able to propose a range of customised strategies to overcome production issues encountered and finally succeeded in generating not only one but three antibodies of interest, thus offering me extra options in terms of final choice and use. During the whole project, Proteogenix strived to ensure maximal quality and to adapt to my needs, and my Account Manager always provided prompt and helpful services and solutions. I can highly commend both the level of expertise and the service I received.”

Dr. Anna Blom Lund University, Sweden

Lund University, Sweden
Dr. Anna Blom, Professor

“I highly recommend ProteoGenix for their fast and efficient services, providing top-quality antibodies suitable for diverse applications. Their exceptional communication, quick turnaround time, and reasonable pricing make them an excellent choice even for non-standard projects.”

Naoya Uchida, M.D The University of Tokyo, Japan

The University of Tokyo, Japan
Naoya Uchida, M.D., Ph.D.

“We requested ProteoGenix’s services for the development of antibodies against a specific surface protein by phage display. Their naive human library was built from 368 donors for maximized diversity. This unique quality and their reactivity convinced us to work with them. They successfully identified various candidates that all bound well and specifically to our antigen. I appreciated their expertise for the high quality of their services as well as their good responses to my questions for this project.”

Khelan Patel - Trident Biopharm Solutions, London, UK

Trident Biopharm Solutions, London, UK
Khelan Patel, Managing Director

“I requested ProteoGenix’s services for the generation of neutralizing anti-COVID-19 antibodies by Phage Display. They designed an optimised strategy for this purpose which led to great results, with 4 antibodies identified as cross-reactive and neutralizing against all the current variants of concerns. During the whole project, Proteogenix strived to ensure the best quality of their final deliverables, especially by including additional screenings against emerging variants as the pandemic evolved. Their proactivity was key to obtaining promising and relevant blocking antibodies in only a few months. I highly recommend them for both their level of expertise and the personalised service they offer.”

Dr. Abbas El Sahili Nanyang Technological University, Singapore

Nanyang Technological University, Singapore
Dr. Abbas El Sahili, Senior Research Fellow

“We are developing a novel immunotherapy and needed a highly potent monoclonal antibody. Currently the development of a novel antibody requires lengthy and expensive humanization process. We thus decided to screen for binders a human antibody library via phage display screening instead of humanizing a murine antibody. Proteogenix proposed just that. We provided our purified target antigen and in only one month several high affinity binders were obtained. We were able to quickly clone and produce a monoclonal antibody from the sequences provided. What should have taken 6 to 8 months was done in 2 for a fraction of the cost and for an equivalent quality.”

FAQ

Need a quote or more information? Contact us!

    Cart (0 Items)

    Your cart is currently empty.

    View Products